Related Experiment Video

Updated: Jan 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

[Dyslipidemia management for secondary prevention in cardiovascular disease: from guidelines to clinical practice]

Alessio Mattesini1, Giulia Masiero2, Lucia Barbieri3

  • 1AOU Careggi, Firenze.

Giornale Italiano Di Cardiologia (2006)
|October 9, 2019
PubMed

Insights

Cardiovascular disease (CVD) remains a major health issue. This document details dyslipidemia treatments, offering a practical guide for managing cholesterol levels in CVD patients.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) persists as a leading cause of death, even with advancements in risk factor management.
  • Lowering LDL-cholesterol through lipid-lowering therapies significantly impacts CVD outcomes for primary and secondary prevention.

Purpose of the Study:

  • To outline the scope of dyslipidemia as a public health problem.
  • To present available therapeutic strategies for dyslipidemia management.
  • To provide a practical pharmacological flowchart for intensive dyslipidemia treatment and monitoring in CVD patients.

Main Methods:

  • Review of clinical trials and meta-analyses on lipid-lowering therapies.
  • Analysis of current international guidelines for CVD management.
  • Development of a practical pharmacological flowchart based on evidence.

Main Results:

  • Dyslipidemia remains a critical challenge in developed nations.
  • Lipid-lowering treatments, especially for LDL-cholesterol, are crucial for CVD prevention and management.
  • A structured approach to pharmacological treatment is essential for optimal patient outcomes.

Conclusions:

  • Intensified and accurate monitoring of dyslipidemia is vital for patients with established CVD.
  • The provided flowchart offers a practical tool for clinicians to manage dyslipidemia effectively.
  • Adherence to guidelines and optimal lipid-lowering therapy can improve CVD morbidity and mortality rates.

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
287
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
557
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
531
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
210